Pay in 4 interest-free payments of $2.50 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
VK2809 is a promising asset for Viking Therapeutics in the MASH market
Partnership Type Partners Benefit in 2024 Cloud Providers AWS
Avalyn Pharma faces moderate competition
6B consolidated revenue exposure: Molex EV contracts (+$420M run-rate)
GLOBANT PORTER'S FIVE FORCES TEMPLATE RESEARCH B_36 VK2809 is a promising assetGo Beyond the Preview Access the Full Strategic Report Globant faces moderate buyer power, rising substitute threats from low cost digital shops, and intense rivalry among agile tech providers while its scale and innovation edge limit supplier and entrant risks; this brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore Globant's competitive dynamics, market pressures, and strategic advantages in detail.
